Effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on murine bone marrow and spleen erythropoiesis

Barrios, L.; Agustini, M.I.; Poletti, O.H.; Juaristi, J.; Brandan, N.C.

Acta Physiologica Pharmacologica et Therapeutica Latinoamericana Organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de Farmacologia 48(1): 18-24

1998


ISSN/ISBN: 0327-6309
PMID: 9504189
Accession: 008579218

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
100 mug/kg of recombinant human granulocyte colony-stimulating factor was injected twice daily into normal adult CF1 female mice for a period of 15 days. After that time we have observed a decrease 59Fe marrow incorporation with a parallel increase in the spleen. During the first 9 days the marrow plus spleen erythroid cells number decreased to 60% of control approximately, but recovered thereafter and were not significantly different from normal values at 12-15 days. In addition, our studies demonstrate that the spleen erythropoiesis is quantitatively more important at the final time than marrow erythropoiesis. For this reason. splenic compensatory erythropoiesis maintained the hematocrit values between normal ranges. Regarding the granulocytic compartment. 15 days of rhG-CSF treatment produce a marked increase in total count of splenic granulocytes (a 7.7 fold rise from control values). Marrow granulocytes shows a 2-fold increment, but considering the absolute counts, bone marrow still was predominant as a granulopoieitc organ. Our results indicate that the spleen is a more important erythropoietic organ than marrow after 15 days of rhG-CSF treatment.